



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 35/00, 48/00, 39/00, C12N 1/20	A1	(11) International Publication Number: WO 00/64457 (43) International Publication Date: 2 November 2000 (02.11.00)
(21) International Application Number: PCT/US00/10954 (22) International Filing Date: 21 April 2000 (21.04.00) (30) Priority Data: 09/298,135 23 April 1999 (23.04.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/298,135 (CIP) Filed on 23 April 1999 (23.04.99) (71) Applicant (for all designated States except US): DALHOUSIE UNIVERSITY [CA/CA]; Technology Transfer Office, 6299 South Street, Arts & Administration Building, Halifax, Nova Scotia B3H 4H6 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): LEE, Song, F. [CA/CA]; 101 Roy Crescent, Bedford, Nova Scotia B4A 4R6 (CA). HALPERIN, Scott, A. [US/CA]; 5 Guildwood Drive, Fall River, Nova Scotia B2T2 J6 (CA).		(74) Agent: REITER, Stephen, E.; Gray Cary Ware & Freidenrich LLP, Suite 1600, 4365 Executive Drive, San Diego, CA 92121 (US). (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: GENETICALLY ENGINEERED ORAL COMMENSAL ORGANISMS AS VACCINES (57) Abstract <p>In accordance with the present invention, there are provided compositions comprising a live oral commensal bacteria, such as a streptococci, that has been genetically modified to express immunogenic fragment(s) of one or more pathogens, such as a mucosal pathogen like <i>B. pertussis</i>, which causes the disease known as whooping cough. The modified organisms are administered orally and/or intranasally. Once an infection of the modified commensal bacteria is established in the oral cavity of the host, the modified organism will continue to express the immunogenic pathogenic fragment(s) so long as the infection persists. Since such oral commensal bacteria generally persist in the oral cavity of humans and other susceptible vertebrates throughout life, the need for booster immunizations is minimized or reduced, providing the host protection against the pathogen throughout life. As native oral commensal organisms are spread from mother to infant as well as between adults by daily contact, invention compositions and methods will be particularly useful for providing immunity in undeveloped countries where conventional vaccines are too expensive to be effectively used.</p>		